Renal ultrastructural alterations induced by various preparations of mefenamic acid

References

• Cimolai N. The potential and promise of mefenamic acid. Expert Rev Clin Pharmacol. 2013;6(3):289–305. doi:10.1586/ecp.13.15.
   PubMed Web of Science ®Google Scholar
• Asif M. Study of anthranylic acid derivatives: mefenamic acid and its various analogues. Am J Med Stud. 2014;2:24–30.
   Google Scholar
• Macintyre IMC, Fink P, McGrouther R, Spence A, Zarifa Z. A single-blind study of naproxen sodium and mefenamic acid in minor trauma. Scott Med J. 1984;29(4):234–237. doi:10.1177/003693308402900406.
   PubMed Web of Science ®Google Scholar
• Ozgoli G, Goli M, Moattar F. Comparison of effects of ginger, mefenamic acid, and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complement Med. 2009;15(2):129–132. doi:10.1089/acm.2008.0311.
   PubMed Web of Science ®Google Scholar
• Venkataraman H, Den Braver MW, Vermeulen NPE, Commandeur JNM. Cytochrome P450-mediated bioactivation of mefenamic acid to quinoneimine intermediates and inactivation by human glutathione S-transferases. Chem Res Toxicol. 2014;27(12):2071–2081. doi:10.1021/tx500288b.
   PubMed Web of Science ®Google Scholar
• Brunner K, Burger HR, Greminger P, Streuli R. Mefenamic acid (Ponstan)-induced acute interstitial nephritis with reversible, severe, non-oliguric renal failure. Schweiz Med Wochenschr. 1985; 115(48):1730–1734.
   PubMedGoogle Scholar
• Onay OS, Erçoban HS, Bayrakci US, Melek E, Cengiz N, Baskin E. Acute, reversible nonoliguric renal failure in two children associated with analgesic-antipyretic drugs. Pediatr Emerg Care. 2009;25(4):263–266. doi:10.1097/PEC.0b013e31819e38d4.
   PubMed Web of Science ®Google Scholar
• Woods KL, Michael J. Mefenamic acid nephropathy. Br Med J (Clin Res Ed). 1981;282(6274):1471. doi:10.1136/bmj.282.6274.1471.
   PubMedGoogle Scholar
• Somchit MN, Sanat F, Hui GE, Wahab SI, Ahmad Z. Mefenamic acid induced nephrotoxicity: an animal model. Adv Pharm Bull. 2014;4(4):401. doi:10.5681/apb.2014.047.
   PubMedGoogle Scholar
• Thanh NTK, Stevenson G, Obatomi DK, Aicher B, Baumeister M, Bach PH. Urinary lipid changes during the development of chemically-induced renal papillary necrosis: a study using mefenamic acid and N-phenylanthranilic acid. biomarkers. 2001;6(6):417–427. doi:10.1080/13547500110057407.
   PubMed Web of Science ®Google Scholar
• Jarrar QB, Hakim MN, Cheema MS, Zakaria ZA. Comparative ultrastructural hepatic alterations induced by free and liposome-encapsulated mefenamic acid. Ultrastruct Pathol. 2017;41:5. doi:10.1080/01913123.2017.1349850.
   Web of Science ®Google Scholar
• Chaffey N, Hayat MA. 2000. Principles and Techniques of Electron Microscopy: Biological Applications. 4th. 543. Cambridge: Cambridge University Press. {pound}65 (Hardback); 2001. doi:10.1006/anbo.2001.1367.
   Google Scholar
• Wyffels JT. Principles and techniques of electron microscopy: biological applications, Fourth Edition, by M. A. Hayat. Microsc Microanal. 2001;7(1):66. doi:10.1017.S1431927601010066.
   PubMedGoogle Scholar
• Hoitsma AJ, Wetzels JFM, Koene RAP. Drug-induced nephrotoxicity. Drug Saf. 1991;6(2):131–147. doi:10.2165/00002018-199106020-00004.
   PubMed Web of Science ®Google Scholar
• Kim SY, Moon A. Drug-induced nephrotoxicity and its biomarkers. Biomol Ther (Seoul). 2012;20(3):268. doi:10.4062/biomolther.2012.20.3.268.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.037.
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4(4):297–305. doi:10.2174/156720107782151269.
   PubMedGoogle Scholar
• Ciolli S, Leoni F, Casini C, Breschi C, Bosi A. Liposomal doxorubicin (Myocet®) enhance the efficacy of bortezomib, dexamethasone plus thalidomide in refractory myeloma. Blood. 2006;108(11):5087LP–5087. http://www.bloodjournal.org/content/108/11/5087.abstract.
   Web of Science ®Google Scholar
• Hu K, Zhu L, Liang H, Hu F, Feng J. Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides. Arch Pharm Res. 2011;34(9):1487. doi:10.1007/s12272-011-0910-9.
   PubMed Web of Science ®Google Scholar
• Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IAJM, Scherphof GL. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer. 1995;61:(5). 716–721. doi:10.1002/ijc.2910610520.
   PubMed Web of Science ®Google Scholar
• Karlowsky JA, Zhanel GG. Concepts on the use of liposomal antimicrobial agents: applications for aminoglycosides. Clin Infect Dis. 1992;15(4):654–667. doi:10.1093/clind/15.4.654.
   PubMed Web of Science ®Google Scholar
• Jarrar QB, Hakim MN, Manraj C, Zainul Z. In vitro characterization and in vivo performance of mefenamic acid-sodium diethyldithiocarbamate based liposomes. Brazilian J Pharm Sci. 2019;55. doi:10.1590/s2175-97902019000117870.
   Web of Science ®Google Scholar
• Boelsterli UA. Mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs. Drug-Induced Liver Disease. Elsevier. 2013;343–367.
   Google Scholar
• Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res. 1997;57:1835–1840.
   PubMed Web of Science ®Google Scholar
• Tiwari BS, Belenghi B, Levine A. Oxidative stress increased respiration and generation of reactive oxygen species, resulting in ATP depletion, opening of mitochondrial permeability transition, and programmed cell death. Plant Physiol. 2002;128(4):1271–1281. doi:10.1104/pp.010999.
   PubMed Web of Science ®Google Scholar
• Uyemura SA, Santos AC, Mingatto FE, Jordani MC, Curti C. Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys. 1997;342(2):231–235. doi:10.1006/abbi.1997.9985.
   PubMed Web of Science ®Google Scholar
• Liu J, Shigenaga MK, Liang-Junyan Y, Mori A, Ames BN. Antioxidant activity of diethyldithiocarbamate. Free Radic Res. 1996;24(6):461–472. doi:10.3109/10715769609088045.
   PubMed Web of Science ®Google Scholar
• Chang TKH, Gonzalez FJ, Waxman DJ. Evaluation of triacetyloleandomycin, α-nasymphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys. 1994;311(2):437–442. doi:10.1006/abbi.1994.1259.
   PubMed Web of Science ®Google Scholar
• Somani SM, Ravi R, Rybak LP. Diethyldithiocarbamate protection against cisplatin nephrotoxicity: antioxidant system. Drug Chem Toxicol. 1995;18(2–3):151–170. doi:10.3109/01480549509014318.
   PubMed Web of Science ®Google Scholar
• DeWoskin RS, Riviere JE. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna. Toxicol Appl Pharmacol. 1992;112(2):182–189. doi:10.1016/0041-008X(92)90186-V.
   PubMed Web of Science ®Google Scholar
• Hidaka S, Funakoshi T, Shimada H, Tsuruoka M, Kojima S. Comparative effects of diethyldithiocarbamate andn-benzyl-d-glucamine dithiocarbamate oncis-diamminedichloroplatinum-induced toxicity in kidney and gastrointestinal tract in rats. J Appl Toxicol. 1995;15(4):267–273. doi:10.1002/(ISSN)1099-1263.
   PubMed Web of Science ®Google Scholar
• Masuda Y, Nakayama N. Protective action of diethyldithiocarbamate and carbon disulfide against renal injury induced by chloroform in mice. Biochem Pharmacol. 1983;32(21):3127–3135. doi:10.1016/0006-2952(83)90194-6.
   PubMed Web of Science ®Google Scholar